Welcome to our dedicated page for MTCR news (Ticker: MTCR), a resource for investors and traders seeking the latest updates and insights on MTCR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MTCR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MTCR's position in the market.
Metacrine, Inc. (NASDAQ:MTCR) reported positive topline results from its Phase 2a trial for MET409, a farnesoid X receptor (FXR) agonist, in combination with empagliflozin in patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The trial demonstrated significant reductions in liver fat content, with a 28% reduction noted in the combination group. All treatment regimens were well-tolerated, with no serious adverse events. Metacrine will prioritize further development of MET642 for inflammatory bowel disease after halting FXR program for NASH.
Metacrine, Inc. (NASDAQ:MTCR) announced interim Phase 2a results for MET642, a farnesoid X receptor agonist, showing significant liver fat reduction in non-alcoholic steatohepatitis (NASH) patients after 16 weeks. The 3 mg cohort showed a 26.9% reduction compared to 7.5% in placebo (p=0.006). MET642 was well-tolerated with no serious adverse events, and the company plans to pivot to a Phase 2 trial for inflammatory bowel disease (IBD) in H1 2022. The decision to halt NASH development was influenced by resource allocation and safety margin concerns.
Metacrine, Inc. (NASDAQ:MTCR) has successfully completed patient enrollment for its Phase 2a trial of MET642, an FXR agonist targeting non-alcoholic steatohepatitis (NASH), surpassing its goal of 180 participants. Interim results from the first 60 patients are expected in Q4 2021, with topline results for all patients anticipated in H1 2022. The trial evaluates safety and efficacy via MRI-PDFF and other metrics at 3 mg and 6 mg doses. The company aims to proceed with further studies in NASH and inflammatory bowel disease following the interim results.
Metacrine, Inc. (NASDAQ:MTCR) announced a virtual R&D Day on September 15, 2021, at 12:00 p.m. ET. This event will highlight the company’s advancements in non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD), alongside a new discovery program. Senior management will present, featuring discussions by renowned experts such as Juan Pablo Frias, M.D., Jesus Rivera-Nieves, M.D., and Stefano Romeo, Ph.D. Registration and live webcasts will be available on the company’s website, offering insights into Metacrine's innovative treatments and ongoing clinical trials.
Metacrine (NASDAQ:MTCR) has announced that its CEO, Preston Klassen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The event will be accessible via a webcast, which will remain available for 90 days post-conference. Metacrine is focused on developing therapies for liver and gastrointestinal diseases, utilizing its proprietary farnesoid X receptor (FXR) platform. Its leading candidates, MET409 and MET642, are in clinical trials for treating NASH, showcasing promising advancements.
Metacrine, Inc. (NASDAQ:MTCR) has announced key clinical milestones and second-quarter 2021 financial results. The interim analysis for the MET642 Phase 2a trial in NASH patients is now expected by early Q4 2021, with topline data anticipated in H1 2022. Additionally, results from the MET409 trial in combination with empagliflozin are on track for Q4 2021. The company reported a cash balance of $74.8 million as of June 30, 2021, allowing for operational funding through 2022, while R&D expenses increased to $11.4 million, reflecting ongoing clinical advancements.
Metacrine, a clinical-stage biopharmaceutical company (NASDAQ:MTCR), announced that its CEO, Preston Klassen, will present at the 2021 Canaccord Genuity Growth Conference on August 12, 2021, at 12:30 p.m. ET. A live webcast will be available for viewing, with a replay accessible for 90 days post-conference. Metacrine focuses on developing therapies for liver and gastrointestinal diseases, leveraging its proprietary farnesoid X receptor (FXR) platform. Its lead candidates, MET409 and MET642, are under investigation for treating NASH.
Metacrine, Inc. (NASDAQ:MTCR) announced it will present new preclinical data at the ECCO 2021 Virtual Congress on July 9, 2021, highlighting FXR activation's potential in treating inflammatory bowel disease (IBD). The presentation, titled 'Activation of FXR Restores Expression of Genes Dysregulated in Human IBD,' indicates FXR agonism can effectively improve pathways related to IBD without immunosuppression. The company plans to initiate a Phase 2a trial for IBD in early 2022, building on its FXR platform with candidates MET409 and MET642 focused on liver and gastrointestinal diseases.
Metacrine, Inc. (NASDAQ:MTCR) announced its participation in the EASL International Liver Congress™ 2021, where it will present data on MET642, a farnesoid X receptor (FXR) agonist designed to treat non-alcoholic steatohepatitis (NASH). The virtual event runs from June 23-26, 2021. Key presentations include:
- Poster PO-393: Focus on MET642's safety profile.
- Poster PO-2388: Study on FXR in biliary atresia.
- Oral Presentation OS-2274: Insights into FXR agonists and disease progression.
Metacrine aims to develop novel therapies for liver diseases.
Metacrine, Inc. (NASDAQ:MTCR) has completed patient enrollment for its Phase 2a trial examining MET409 combined with empagliflozin (Jardiance®) for treating type 2 diabetes and non-alcoholic steatohepatitis (NASH). Topline data are set to be reported in Q4 2021. The trial, involving over 120 patients, aims to assess safety and liver fat reduction. Metacrine emphasizes the importance of combination therapies for NASH patients, as SGLT-2 inhibitors may provide cardiovascular and renal benefits alongside potential liver fat reduction.
FAQ
What is the market cap of MTCR (MTCR)?
